KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Gsk (GSK) over the last 17 years, with Q3 2025 value amounting to -$61.5 billion.

  • Gsk's Total Liabilities fell 613.61% to -$61.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$61.5 billion, marking a year-over-year decrease of 613.61%. This contributed to the annual value of -$59.3 billion for FY2024, which is 20314.13% down from last year.
  • Per Gsk's latest filing, its Total Liabilities stood at -$61.5 billion for Q3 2025, which was down 613.61% from -$59.9 billion recorded in Q2 2025.
  • Gsk's Total Liabilities' 5-year high stood at $77.9 billion during Q4 2021, with a 5-year trough of -$83.6 billion in Q2 2022.
  • For the 5-year period, Gsk's Total Liabilities averaged around -$42.0 billion, with its median value being -$59.3 billion (2025).
  • In the last 5 years, Gsk's Total Liabilities soared by 6901.08% in 2022 and then plummeted by 20378.59% in 2024.
  • Quarter analysis of 5 years shows Gsk's Total Liabilities stood at $77.9 billion in 2021, then dropped by 24.6% to $58.7 billion in 2022, then fell by 2.3% to $57.4 billion in 2023, then plummeted by 203.79% to -$59.5 billion in 2024, then fell by 3.32% to -$61.5 billion in 2025.
  • Its last three reported values are -$61.5 billion in Q3 2025, -$59.9 billion for Q2 2025, and -$59.3 billion during Q1 2025.